13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001652044
Total reported value
$99.1B
$99.1B
42 檔
1.3%
During the Q3 2024 filing period, Alphabet Inc. (CIK: 0001652044) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $99.1B across 42 reported positions.
During Q3 2024, Alphabet Inc.'s portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | GTLB | Gitlab Inc-cl A | Stock-Tech | 27.30% | -1.39% | — | |
| 2 | ARM | Arm Holdings Plc-adr | Stock-Tech | 15.22% | -6.69% | — | |
| 3 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 10.48% | -7.41% | -19.80% | |
| 4 | FRSH | Freshworks Inc-cl A | Stock-Other | 10.10% | -3.07% | +31.37% | |
| 5 | CRWD | Crowdstrike Holdings Inc - A | Stock-Tech | 6.52% | — | — | |
| 6 | PATH | Uipath Inc - Class A | Stock-Tech | 4.89% | -1.86% | — | |
| 7 | TEM | Tempus Ai Inc-cl A | Stock-Healthcare | 4.77% | -1.66% | — | |
| 8 | PL | Planet Labs Pbc | Stock-Industrials | 3.87% | -23.35% | — | |
| 9 | DXCM | Dexcom Inc | Stock-Healthcare | 3.77% | — | — | |
| 10 | ✓ | Verve Therapeutics Inc | Stock-Other | 3.24% | — | — | |
| 11 | PRME | Prime Medicine Inc | Stock-Other | 3.16% | -1.38% | — | |
| 12 | SNOW | Snowflake Inc | Stock-Tech | 0.71% | — | -78.61% | |
| 13 | SANA | Sana Biotechnology Inc | Stock-Other | 0.64% | -0.19% | — | |
| 14 | RLAY | Relay Therapeutics Inc | Stock-Other | 0.60% | -0.36% | — | |
| 15 | VERA | Vera Therapeutics Inc | Stock-Other | 0.58% | -0.23% | — | |
| 16 | OSCR | Oscar Health Inc - Class A | Stock-Healthcare | 0.55% | -0.13% | — | |
| 17 | LYEL | Lyell Immunopharma, Inc. | Stock-Other | 0.44% | — | — | |
| 18 | BEAM | Beam Therapeutics Inc | Stock-Other | 0.43% | -0.18% | — | |
| 19 | GLUE | Monte Rosa Therapeutics Inc | Stock-Other | 0.42% | -0.27% | — | |
| 20 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 0.31% | — | — | |
| 21 | TCRX | Tscan Therapeutics Inc | Stock-Other | 0.29% | — | — | |
| 22 | DM* | Desktop Metal Inc-a | Stock-Other | 0.28% | — | — | |
| 23 | FHTX | Foghorn Therapeutics Inc | Stock-Other | 0.25% | — | — | |
| 24 | BHILQ | Benson Hill Inc | Stock-Other | 0.17% | — | — | |
| 25 | AUTL | Autolus Therapeutics PLC | Stock-Other | 0.14% | -0.02% | — | |
| 26 | BRNS | Barinthus Biotherapeutics Pl | Stock-Other | 0.10% | — | — | |
| 27 | TNYA | Tenaya Therapeutics Inc | Stock-Other | 0.10% | -0.02% | EXIT | |
| 28 | GUTS | Fractyl Health Inc | Stock-Other | 0.09% | — | — | |
| 29 | EXK | Exact Sciences CORP | Stock-Materials | 0.09% | — | — | |
| 30 | KRON1USD | Kronos Bio Inc | Stock-Other | 0.08% | — | — | |
| 31 | TSHA | Taysha Gene Therapies Inc | Stock-Other | 0.07% | — | — | |
| 32 | SPRO | Spero Therapeutics Inc | Stock-Other | 0.06% | -0.05% | — | |
| 33 | ✓ | Rapt Therapeutics Inc | Stock-Other | 0.06% | — | — | |
| 34 | HYPR | Hyperfine Inc | Stock-Other | 0.05% | -0.02% | — | |
| 35 | RANI | Rani Therapeutics Holdings-a | Stock-Other | 0.05% | — | — | |
| 36 | WGS | Genedx Holdings CORP | Stock-Other | 0.05% | — | — | |
| 37 | ALEC | Alector Inc | Stock-Other | 0.04% | — | — | |
| 38 | QNCX | Quince Therapeutics, Inc. | Stock-Other | 0.01% | — | — | |
| 39 | RGEN | Repligen CORP | Stock-Healthcare | — | — | — | |
| 40 | FULC | Fulcrum Therapeutics Inc | Stock-Other | — | — | — | |
| 41 | HLTHQ | Cue Health Inc | Stock-Other | — | — | — | |
| 42 | NVTA1EUR | Invitae CORP | Stock-Other | — | — | — |
According to official SEC Form 13F filings, Alphabet Inc. reported a total U.S. public equity portfolio value of $99.1B across 42 disclosed positions in Q3 2024.
During Q3 2024, Alphabet Inc.'s top holdings by market value included GTLB (27.3%)、ARM (15.2%)、RVMD (10.5%). The largest single position, GTLB, represented 27.3% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including GTLB, ARM, RVMD) accounted for 1.3% of total reported equity market value during Q3 2024.
In Q3 2024, Alphabet Inc. made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.